Cargando…
Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma
Adrenacarcinomas are rare, and hypoglycemic syndrome resulting from the secretion of insulin-like growth factor II (IGF-II) by these tumors have been described infrequently. This study describes the case of a young woman with severe persistent hypoglycemia and a large adrenal tumor and discusses the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097138/ https://www.ncbi.nlm.nih.gov/pubmed/27857836 http://dx.doi.org/10.1530/EDM-16-0101 |
_version_ | 1782465561579487232 |
---|---|
author | Marchetti, Katia Regina Pereira, Maria Adelaide Albergaria Lichtenstein, Arnaldo Paiva, Edison Ferreira |
author_facet | Marchetti, Katia Regina Pereira, Maria Adelaide Albergaria Lichtenstein, Arnaldo Paiva, Edison Ferreira |
author_sort | Marchetti, Katia Regina |
collection | PubMed |
description | Adrenacarcinomas are rare, and hypoglycemic syndrome resulting from the secretion of insulin-like growth factor II (IGF-II) by these tumors have been described infrequently. This study describes the case of a young woman with severe persistent hypoglycemia and a large adrenal tumor and discusses the physiopathological mechanisms involved in hypoglycemia. The case is described as a 21-year-old woman who presented with 8 months of general symptoms and, in the preceding 3 months, with episodes of mental confusion and visual blurring secondary to hypoglycemia. A functional assessment of the adrenal cortex revealed ACTH-independent hypercortisolism and hyperandrogenism. Hypoglycemia, hypoinsulinemia, low C-peptide and no ketones were also detected. An evaluation of the GH–IGF axis revealed GH blockade (0.03; reference: up to 4.4 ng/mL), greatly reduced IGF-I levels (9.0 ng/mL; reference: 180–780 ng/mL), slightly reduced IGF-II levels (197 ng/mL; reference: 267–616 ng/mL) and an elevated IGF-II/IGF-I ratio (21.9; reference: ~3). CT scan revealed a large expansive mass in the right adrenal gland and pulmonary and liver metastases. During hospitalization, the patient experienced frequent difficult-to-control hypoglycemia and hypokalemia episodes. Octreotide was ineffective in controlling hypoglycemia. Due to unresectability, chemotherapy was tried, but after 3 months, the patient’s condition worsened and progressed to death. In conclusion, our patient presented with a functional adrenal cortical carcinoma, with hyperandrogenism associated with hypoinsulinemic hypoglycemia and blockage of the GH–IGF-I axis. Patient’s data suggested a diagnosis of hypoglycemia induced by an IGF-II or a large IGF-II-producing tumor (low levels of GH, greatly decreased IGF-I, slightly decreased IGF-II and an elevated IGF-II/IGF-I ratio). LEARNING POINTS: Hypoglycemyndrome resulting from the secretion of insulin-like growth factor II (IGF-II) by adrenal tumors is a rare condition. Hypoinsulinemic hypoglycemia associated with hyperandrogenism and blockage of the GH–IGF-I axis suggests hypoglycemia induced by an IGF-II or a large IGF-II-producing tumor. Hypoglycemia in cases of NICTH should be treated with glucocorticoids, glucagon, somatostatin analogs and hGH. |
format | Online Article Text |
id | pubmed-5097138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-50971382016-11-17 Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma Marchetti, Katia Regina Pereira, Maria Adelaide Albergaria Lichtenstein, Arnaldo Paiva, Edison Ferreira Endocrinol Diabetes Metab Case Rep Insight into Disease Pathogenesis or Mechanism of Therapy Adrenacarcinomas are rare, and hypoglycemic syndrome resulting from the secretion of insulin-like growth factor II (IGF-II) by these tumors have been described infrequently. This study describes the case of a young woman with severe persistent hypoglycemia and a large adrenal tumor and discusses the physiopathological mechanisms involved in hypoglycemia. The case is described as a 21-year-old woman who presented with 8 months of general symptoms and, in the preceding 3 months, with episodes of mental confusion and visual blurring secondary to hypoglycemia. A functional assessment of the adrenal cortex revealed ACTH-independent hypercortisolism and hyperandrogenism. Hypoglycemia, hypoinsulinemia, low C-peptide and no ketones were also detected. An evaluation of the GH–IGF axis revealed GH blockade (0.03; reference: up to 4.4 ng/mL), greatly reduced IGF-I levels (9.0 ng/mL; reference: 180–780 ng/mL), slightly reduced IGF-II levels (197 ng/mL; reference: 267–616 ng/mL) and an elevated IGF-II/IGF-I ratio (21.9; reference: ~3). CT scan revealed a large expansive mass in the right adrenal gland and pulmonary and liver metastases. During hospitalization, the patient experienced frequent difficult-to-control hypoglycemia and hypokalemia episodes. Octreotide was ineffective in controlling hypoglycemia. Due to unresectability, chemotherapy was tried, but after 3 months, the patient’s condition worsened and progressed to death. In conclusion, our patient presented with a functional adrenal cortical carcinoma, with hyperandrogenism associated with hypoinsulinemic hypoglycemia and blockage of the GH–IGF-I axis. Patient’s data suggested a diagnosis of hypoglycemia induced by an IGF-II or a large IGF-II-producing tumor (low levels of GH, greatly decreased IGF-I, slightly decreased IGF-II and an elevated IGF-II/IGF-I ratio). LEARNING POINTS: Hypoglycemyndrome resulting from the secretion of insulin-like growth factor II (IGF-II) by adrenal tumors is a rare condition. Hypoinsulinemic hypoglycemia associated with hyperandrogenism and blockage of the GH–IGF-I axis suggests hypoglycemia induced by an IGF-II or a large IGF-II-producing tumor. Hypoglycemia in cases of NICTH should be treated with glucocorticoids, glucagon, somatostatin analogs and hGH. Bioscientifica Ltd 2016-11-04 2016 /pmc/articles/PMC5097138/ /pubmed/27857836 http://dx.doi.org/10.1530/EDM-16-0101 Text en This is an Open Access article distributed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) . |
spellingShingle | Insight into Disease Pathogenesis or Mechanism of Therapy Marchetti, Katia Regina Pereira, Maria Adelaide Albergaria Lichtenstein, Arnaldo Paiva, Edison Ferreira Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma |
title | Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma |
title_full | Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma |
title_fullStr | Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma |
title_full_unstemmed | Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma |
title_short | Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma |
title_sort | refractory hypoglycemia in a patient with functional adrenal cortical carcinoma |
topic | Insight into Disease Pathogenesis or Mechanism of Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097138/ https://www.ncbi.nlm.nih.gov/pubmed/27857836 http://dx.doi.org/10.1530/EDM-16-0101 |
work_keys_str_mv | AT marchettikatiaregina refractoryhypoglycemiainapatientwithfunctionaladrenalcorticalcarcinoma AT pereiramariaadelaidealbergaria refractoryhypoglycemiainapatientwithfunctionaladrenalcorticalcarcinoma AT lichtensteinarnaldo refractoryhypoglycemiainapatientwithfunctionaladrenalcorticalcarcinoma AT paivaedisonferreira refractoryhypoglycemiainapatientwithfunctionaladrenalcorticalcarcinoma |